Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2026 18:14 ET | Source: AgomAb Therapeutics NV

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Agomab Therapeutics NV today reported financial results for the full year period ended December 31, 2025, and confirmed its outlook for 2026.
March 26, 2026 07:00 ET | Source: AgomAb Therapeutics N.V.

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Agomab today announced that the USPTO granted a patent covering the composition of matter of AGMB-447.
January 08, 2026 05:00 ET | Source: AgomAb Therapeutics N.V.

Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort

Agomab today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants.